Mehlika Toy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1364323/publications.pdf

Version: 2024-02-01

38	813	16	28
papers	citations	h-index	g-index
38	38	38	1389
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective. Gastroenterology, 2010, 138, 522-530.	1.3	110
2	Emerging Technologies for Point-of-Care Management of HIV Infection. Annual Review of Medicine, 2015, 66, 387-405.	12.2	97
3	Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infectious Diseases, 2011, 11, 337.	2.9	72
4	Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30. The Lancet Global Health, 2019, 7, e1180-e1188.	6.3	58
5	Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China. Hepatology, 2014, 60, 46-55.	7.3	41
6	Cost-effectiveness of Augmenting Universal Hepatitis B Vaccination With Immunoglobin Treatment. Pediatrics, 2013, 131, e1135-e1143.	2.1	39
7	Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnology Advances, 2015, 33, 178-190.	11.7	38
8	Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. Clinical Infectious Diseases, 2022, 74, 210-217.	5.8	36
9	Knowledge, attitudes and medical practice regarding hepatitis B prevention and management among healthcare workers in Northern Vietnam. PLoS ONE, 2019, 14, e0223733.	2.5	30
10	The case for simplifying and using absolute targets for viral hepatitis elimination goals. Journal of Viral Hepatitis, 2021, 28, 12-19.	2.0	28
11	Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology, 2009, 50, 743-751.	7.3	27
12	Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019. PLoS ONE, 2020, 15, e0239393.	2.5	26
13	Transmission routes of hepatitis B virus infection in chronic hepatitis B patients in The Netherlands. Journal of Medical Virology, 2008, 80, 399-404.	5.0	25
14	The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. European Journal of Health Economics, 2012, 13, 663-676.	2.8	24
15	Knowledge, attitudes and practices of hepatitis B prevention and immunization of pregnant women and mothers in northern Vietnam. PLoS ONE, 2019, 14, e0208154.	2.5	23
16	Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS ONE, 2015, 10, e0139876.	2.5	22
17	Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income. Value in Health, 2020, 23, 1552-1560.	0.3	16
18	A Mathematical Approach for Evaluating Markov Models in Continuous Time without Discrete-Event Simulation. Medical Decision Making, 2013, 33, 767-779.	2.4	15

#	Article	IF	Citations
19	Population Health And Economic Impacts Of Reaching Chronic Hepatitis B Diagnosis And Treatment Targets In The US. Health Affairs, 2018, 37, 1033-1040.	5.2	13
20	Cost-effectiveness of viral hepatitis B & Damp; C treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 973-985.	2.4	12
21	Barriers to Disease Monitoring and Liver Cancer Surveillance Among Patients with Chronic Hepatitis B in the United States. Journal of Community Health, 2019, 44, 610-625.	3.8	11
22	Hepatitis Delta Virus Epidemiology in the Industrialized World. AIDS Reviews, 2021, 22, 203-212.	1.0	9
23	Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California. Hepatology, Medicine and Policy, 2018, 3, 6.	1.7	8
24	The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia. Liver International, 2022, 42, 16-25.	3.9	7
25	Hepatitis Delta Virus Infection: A Large Burden After All?. Journal of Infectious Diseases, 2020, 221, 1573-1575.	4.0	6
26	The Hep B Calculator: an online tool for cost-effectiveness analyses of treatment. The Lancet Gastroenterology and Hepatology, 2019, 4, 668.	8.1	4
27	Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections. Sexually Transmitted Diseases, 2022, 49, 517-525.	1.7	4
28	Preventing hepatocellular carcinoma: the crucial role of chronic hepatitis B monitoring and antiviral treatment. Hepatic Oncology, 2014, 1, 255-257.	4.2	3
29	Costs and health impact of delayed implementation of a national hepatitis B treatment program in China. Journal of Global Health, 0, 12 , .	2.7	3
30	Hepatitis B cure. Current Opinion in HIV and AIDS, 2020, 15, 208-212.	3.8	2
31	Letter to the editor: Importance of universal screening for chronic hepatitis B infection in adults in the United States. Hepatology, 2022, 75, 1062-1063.	7.3	2
32	Trends in Prevalence and Predictors of Hepatitis B Virus Vaccination in the General United States Population from 1999-2014. Gastroenterology, 2017, 152, S1052.	1.3	1
33	Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment. Current Hepatology Reports, 2019, 18, 357-362.	0.9	1
34	County and Ethnic-Specific HBV Prevalence and Total Disease Burden in California: Estimates by Disease Status Using Community-Based Real-World Data. Gastroenterology, 2017, 152, S1083.	1.3	0
35	Title is missing!. , 2020, 15, e0239393.		0
36	Title is missing!. , 2020, 15, e0239393.		0

#	Article	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0239393.		0
38	Title is missing!. , 2020, 15, e0239393.		0